This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
GE HealthCare Wins FDA Clearances for Next-Gen SIGNA MRI Portfolio
by Zacks Equity Research
GEHC wins FDA clearance for three SIGNA MRI innovations, boosting AI-driven workflows, sustainability and precision imaging capabilities.
ISRGPositive Net Change CAHPositive Net Change VCYTNegative Net Change GEHCPositive Net Change
medical medical-devices
AMN Q4 Earnings Meet Estimates, Revenues Beat, Gross Margin Contracts
by Zacks Equity Research
AMN Healthcare Services posts a 70% drop in Q4 EPS but forecasts up to 80% revenue growth in Q1 2026, which drives shares higher in after-hours trading.
ISRGPositive Net Change CAHPositive Net Change MCKPositive Net Change AMNPositive Net Change
earnings medical medical-devices
ITGR Shares Down Despite Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Integer Holdings beats Q4 estimates with 23% EPS growth and margin gains, but shares slide 4% as softer 2026 guidance tempers investor enthusiasm.
ISRGPositive Net Change VCYTNegative Net Change ITGRPositive Net Change GEHCPositive Net Change
earnings medical medical-devices
Hims & Hers Accelerates AI Preventive Care and Platform Strategy
by Debanjana Dey
HIMS is accelerating AI-driven preventive care with new menopause, low testosterone and multi-cancer testing, deepening its personalized digital health platform.
AMWLNegative Net Change HIMSNegative Net Change TEMNegative Net Change
medical medical-devices
Should You Buy Equinix (EQIX) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
EQIXPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Redwood Trust (RWT) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
RWTNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
BSX vs. ABT: Which MedTech Stock is the Better Investment Now?
by Moumi Mondal
Abbott edges out Boston Scientific in the MedTech faceoff, with valuation appeal, strong CGM momentum and strategic deals boosting its investment case.
ABTPositive Net Change BSXNegative Net Change
medical medical-devices
SENS Eversense 365 Integrated With twiist Gains Full Availability
by Zacks Equity Research
Senseonics rolls out Eversense 365 integrated with Sequel's twiist AID system, aiming to boost CGM adoption with its year-long wear advantage.
ABTPositive Net Change DXCMPositive Net Change TNDMPositive Net Change SENSNegative Net Change
medical medical-devices
STAA Gains FDA Nod to Expand EVO ICL Age Indication to 60 Years
by Zacks Equity Research
STAAR Surgical jumps 8% after the FDA expands the EVO ICL age range to 21-60, backed by strong safety data and rising demand for LASIK alternatives.
ISRGPositive Net Change CAHPositive Net Change MCKPositive Net Change STAANegative Net Change
medical medical-devices
Can Platform Strength Support Hims & Hers Stock Before Q4 Earnings?
by Debanjana Dey
HIMS fourth-quarter 2025 results are likely to benefit from new specialties and global expansion, but higher costs and GLP-1 scrutiny could cloud earnings.
VEEVNegative Net Change INSPNegative Net Change AMWLNegative Net Change HIMSNegative Net Change
earnings medical medical-devices